insights_auto
Why is 4547 down 2.78%?
Dive Deeperchevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
ÂĄ4,370.00
arrow_downward
-2.78%(-125.00) 1D
Nov 20, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
ÂĄ4,475
High
ÂĄ4,510
Low
ÂĄ4,345
Mkt. cap
203.39B
Avg. vol.
109.68K
Volume
155.50K
Dividend
2.86%
Quarterly dividend
ÂĄ31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.20
52-wk high
ÂĄ5,040
52-wk low
ÂĄ3,500
EPS
ÂĄ270
Shares outstanding
46.72M
No. of employees
2K
Open
ÂĄ4,475
High
ÂĄ4,510
Low
ÂĄ4,345
Mkt. cap
203.39B
Avg. vol.
109.68K
Volume
155.50K
Dividend
2.86%
Quarterly dividend
ÂĄ31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.20
52-wk high
ÂĄ5,040
52-wk low
ÂĄ3,500
EPS
ÂĄ270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
Traders Union
·
3 hours ago
Seventeen of the twenty largest S&P 500 drops began below the 200-day moving average, Ryan Detrick notes
Beinsure
·
1 hour ago
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
24/7 Wall St.
·
2 hours ago
The S&P 500 Just Plunged 9% in a Week. Charlie Munger Once Lost 53% in Two Years. Here's His Test for a 66-Year-Old With $2 Million
cwibc.co.id
·
13 minutes ago
S&P 500 Tech Sector Falls 23% Into Bear Market
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp